Osteoprotegerin ELISA Kit

Catalog No. ABIN411341

This Colorimetric ELISA kit is designed for the quantitative measurement of Human Osteoprotegerin. There are 8 publications available.

Quick Overview for Osteoprotegerin ELISA Kit (ABIN411341)

Target: Osteoprotegerin (TNFRSF11B) (Tumor Necrosis Factor Receptor Superfamily, Member 11b (TNFRSF11B))

Binding Specificity: AA 22-401

Reactivity: Human

Detection Method: Colorimetric

Method Type: Sandwich ELISA

Detection Range: 93.7 pg/mL - 6000 pg/mL

Application: ELISA

Sample Type: Cell Culture Supernatant, Serum, Plasma (heparin), Plasma (EDTA), Saliva, Urine

Product Details Osteoprotegerin ELISA Kit

Minimum Detection Limit: 93.7 pg/mL

Purpose: Sandwich Human OPG (TNFRSF11B) / Osteoprotegerin ELISA Kit to quantitate Human TNFRSF11B in cell culture supernatants, serum, plasma (heparin, EDTA) , saliva and urine.

Analytical Method: Quantitative

Specificity: Expression system for standard: NS0
Immunogen sequence: E22-L401

Capture antibody and Detection antibody: polyclonal antibody from goat, polyclonal antibody from goat

Cross-Reactivity (Details): There is no detectable cross-reactivity with other relevant proteins.

Sensitivity: < 5 pg/mL

Components:

1. Pre-coated 96-well strip microplate
2. Standard
3. Biotinylated antibody (100x)
4. Avidin-Biotin-Peroxidase Complex (100x)
5. Sample Diluent
6. Antibody Diluent
7. Avidin-Biotin-Peroxidase Diluent
8. Color Developing Reagent (TMB)
9. Stop Solution
10. Wash Buffer (25x)
11. Adhesive plate sealers

Material not included: Microplate Reader capable of reading absorbance at 450nm. Incubator. Automated plate washer (optional). Pipettes and pipette tips capable of precisely dispensing 0.5 μL through 1 mL volumes of aqueous solutions. Multichannel pipettes are recommended for large amount of samples. Deionized or distilled water. 500 mL graduated cylinders. Test tubes for dilution.

Application Details

Application Notes: Before using Kit, spin tubes and bring down all components to bottom of tube. Duplicate well assay was recommended for both standard and sample testing.

Sample Volume: 100 μL

Plate: Pre-coated

Protocol: ELISA Kit is based on standard sandwich enzyme-linked immune-sorbent assay technology. An antibody has been precoated onto 96-well plates. Standards and test samples are added to the wells, a biotinylated detection antibody specific for target is added subsequently and then followed by washing with PBS or TBS buffer. Avidin-Biotin-Peroxidase Complex was added and unbound conjugates were washed away with PBS or TBS buffer. HRP substrate TMB was used to visualize HRP enzymatic reaction. TMB was catalyzed by HRP to produce a blue color product that changed into yellow after adding acidic stop solution. The density of yellow is proportional to the target amount in sample captured in plate.

Assay Precision: Intra-Assay Precision (CV%): 7.9%, 5.8%, 4.2%
Inter-Assay Precision (CV%): 8.9%, 7.4%, 5.1%

Restrictions: For Research Use only

Handling

Handling Advice: Avoid multiple freeze-thaw cycles.

Storage: -20 °C,4 °C

Storage Comment: Store at 4°C for 6 months, at -20°C for 12 months. Avoid multiple freeze-thaw cycles (Ships with gel ice, can store for up to 3 days in room temperature. Freeze upon receiving.)

Expiry Date: 12 months

References for Osteoprotegerin ELISA Kit (ABIN411341)

Häussling, Aspera-Werz, Rinderknecht, Springer, Arnscheidt, Menger, Histing, Nussler, Ehnert: "3D Environment Is Required In Vitro to Demonstrate Altered Bone Metabolism Characteristic for Type 2 Diabetics." in: International journal of molecular sciences, Vol. 22, Issue 6, (2021) (PubMed).

Park, Kim, Kim, Lee, Kim, Park, Chung: "Loss of RUNX3 expression inhibits bone invasion of oral squamous cell carcinoma." in: Oncotarget, Vol. 8, Issue 6, pp. 9079-9092, (2018) (PubMed).

Sherief, Dawood, Ali, Sherbiny, Kamal, Elshanshory, Alazez, Alhady, Nour, Mokhtar: "Premature atherosclerosis in children with beta-thalassemia major: New diagnostic marker." in: BMC pediatrics, Vol. 17, Issue 1, pp. 69, (2018) (PubMed).

Mamolini, Cervellati, Greco, Carrieri, Massari, Crivellari, Scapoli, Bonaccorsi: "VDR, RANKL and OPG polymorphisms as possible predisposing cofactors of postmenopausal osteoporosis: explorative study in Italian population." in: Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology, pp. 1-5, (2017) (PubMed).

Cervellati, Romani, Cremonini, Bergamini, Fila, Squerzanti, Greco, Massari, Bonaccorsi: "Higher Urinary Levels of 8-Hydroxy-2'-deoxyguanosine Are Associated with a Worse RANKL/OPG Ratio in Postmenopausal Women with Osteopenia." in: Oxidative medicine and cellular longevity, Vol. 2016, pp. 6038798, (2015) (PubMed).

Chen, Li, Liu, Wang, Xie, Liu, Hou, Chang, Du: "Canonical Wnt signaling is required for Panax notoginseng saponin-mediated attenuation of the RANKL/OPG ratio in bone marrow stromal cells during osteogenic differentiation." in: Phytomedicine : international journal of phytotherapy and phytopharmacology, Vol. 19, Issue 11, pp. 1029-34, (2012) (PubMed).

Taylan, Sari, Akinci, Bilge, Kozaci, Akar, Colak, Yalcin, Gunay, Akkoc: "Biomarkers and cytokines of bone turnover: extensive evaluation in a cohort of patients with ankylosing spondylitis." in: BMC musculoskeletal disorders, Vol. 13, pp. 191, (2012) (PubMed).

Xu, Wang, Lu, Xu: "Osteoprotegerin and RANKL in the pathogenesis of rheumatoid arthritis-induced osteoporosis." in: Rheumatology international, Vol. 32, Issue 11, pp. 3397-403, (2012) (PubMed).

Target Details for Osteoprotegerin

Target: Osteoprotegerin (TNFRSF11B) (Tumor Necrosis Factor Receptor Superfamily, Member 11b (TNFRSF11B))

Alternative Name: Osteoprotegerin (OPG)

Target Type: Chemical

Background:

Background: Osteoprotegerin (OPG) is identical to osteoclastogenesis inhibitory factor (OCIF), a soluble member of the tumor-necrosis factor receptor family that inhibits osteoclastogenesis. OPG is considered to play an important role in the regulation of bone resorption by modifying osteoclast differentiation. Osteoprotegerin is an independent risk factor for the progression of atherosclerosis and onset of cardiovascular disease. It can act as a soluble factor in the regulation of bone mass and imply a utility for OPG in the treatment of osteoporosis associated with increased osteoclast activity. OPG system may play a critical role in the development of osteolytic bone disease in multiple myeloma and that targeting this system may have therapeutic potential. OPG also plays a role in the vascular system. The standard product used in this kit is recombinant OPG, a 55KDa glycoprotein.

Gene Full Name: TNF receptor superfamily member 11b

Gene ID: 4982

UniProt: O00300